Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Devices & Dosimetry

Fractional non ablative 675 nm diode laser versus low fluence high frequency Q- switched 1064 nm nd: YAG laser in the treatment of melasma: a comparative split face trial

Adverse events were mild and transient. Fractional non-ablative 675 nm diode laser is more effective and equally safe compared to Q-switched 1064 nm Nd:YAG laser in treating facial melasma, offering a promising modality for patients with recalcitrant hyperpigmentation.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors compared a fractional non-ablative 675 nm diode laser with a Q-switched 1064 nm Nd:YAG laser in 30 women with facial melasma using a split-face design. Both lasers reduced MASI and dermoscopic scores, and the authors report the 675 nm laser showed greater improvement and mild, transient adverse events.

Participants
30
Who or what was studied
Thirty female patients with bilateral facial melasma
Wavelengths
675, 1064 nm
Limits stated in the abstract
The abstract does not describe a control group or sample size justification, and follow-up ends at 12 weeks.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Melasma is a chronic, relapsing pigmentary disorder that poses a significant therapeutic challenge, particularly in individuals with darker skin types. Laser therapies have shown promise in targeting both epidermal and dermal melanin deposits. The study aimed to compare the efficacy and safety of fractional non-ablative 675 nm diode laser and Q-switched 1064 nm Nd:YAG laser in the treatment of facial melasma using a split-face design. Thirty female patients with bilateral facial melasma were enrolled in a prospective, split-face trial. Each received five treatment sessions at two-week intervals: the right side with 675 nm diode laser and the left with 1064 nm Q-switched Nd:YAG laser. Clinical efficacy was assessed using the Melasma Area and Severity Index (MASI), dermoscopic scoring, and post-therapy lightening grade at baseline and 12 weeks post-treatment. Both modalities resulted in significant reductions in MASI and dermoscopic scores (p < 0.05). The 675 nm laser showed superior improvement, with a greater proportion of patients achieving excellent lightening. Adverse events were mild and transient. Fractional non-ablative 675 nm diode laser is more effective and equally safe compared to Q-switched 1064 nm Nd:YAG laser in treating facial melasma, offering a promising modality for patients with recalcitrant hyperpigmentation.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Wavelength
675 nm, 1064 nm

How to read a trial: what to check before relying on this kind of research.

Terms in this paper: Laser, Fluence, Melanin, GRADE. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies